10x Genomics, Inc.TXGEarnings & Financial Report
10x Genomics, Inc. is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.
TXG Q4 2025 Key Financial Metrics
Revenue
$166.0M
Gross Profit
$113.0M
Operating Profit
$-19.5M
Net Profit
$-16.3M
Gross Margin
68.1%
Operating Margin
-11.8%
Net Margin
-9.8%
YoY Growth
0.6%
EPS
$-0.13
Financial Flow
10x Genomics, Inc. Q4 2025 Financial Summary
10x Genomics, Inc. reported revenue of $166.0M for Q4 2025, with a net profit of $-16.3M (-9.8% margin). Cost of goods sold was $53.0M, operating expenses totaled $132.6M.
Key Financial Metrics
| Total Revenue | $166.0M |
|---|---|
| Net Profit | $-16.3M |
| Gross Margin | 68.1% |
| Operating Margin | -11.8% |
| Report Period | Q4 2025 |
10x Genomics, Inc. Annual Revenue by Year
10x Genomics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $642.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $642.8M |
| 2024 | $610.8M |
| 2023 | $618.7M |
| 2022 | $516.4M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $141.0M | $153.1M | $151.7M | $165.0M | $154.9M | $172.9M | $149.0M | $166.0M |
| YoY Growth | 5.0% | 4.3% | -1.3% | -10.3% | 9.8% | 12.9% | -1.7% | 0.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $922.9M | $929.7M | $937.8M | $918.6M | $903.4M | $980.0M | $1.03B | $1.04B |
| Liabilities | $204.1M | $205.6M | $215.0M | $208.5M | $196.5M | $206.7M | $242.2M | $245.0M |
| Equity | $718.8M | $724.1M | $722.8M | $710.1M | $706.9M | $773.3M | $785.1M | $796.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.7M | $7.5M | $21.6M | $-6.7M | $34.4M | $17.7M | $43.2M | $40.8M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
GRAL
GRAIL, Inc.
Revenue
$36.2M
Net Profit
$-89.0M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
DFTX
Mind Medicine (MindMed) Inc.
Revenue
$906.0K
Net Profit
$-23.9M
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Revenue
$38.4M
Net Profit
$-38.0M
ASMB
ASSEMBLY BIOSCIENCES, INC.
Revenue
$10.8M
Net Profit
$-9.2M
DTIL
PRECISION BIOSCIENCES INC
Revenue
$13.0K
Net Profit
$-21.8M